Study on the effect of Huoxue Jiedu Formula on apoptosis of submaxillary gland cells in mice with Sjögren syndrome

  • role: First author第一作者
  • Affiliation:

    Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing 100029, China

  • Introduction:
WANG Dongfeng1,  
  • Affiliation:

    Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China

ZHU Yuelan2,  
  • Affiliation:

    Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China

HOU Xiujuan2,  
  • Affiliation:

    Tongzhou Branch of Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 101121, China

GU Xinyi3,  
  • Affiliation:

    Huguosi Traditional Chinese Medicine Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100035, China

HU Hai4,  
  • role: Corresponding author通信作者
  • Affiliation:

    Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China

  • Email:lifangkai1324@163.com
  • Introduction:LI Fangkai, Masters Degree, Associate Chief Physician. Dongfang Hospital, Beijing University of Chinese Medicine, No.6, 1st Area, Fangxing Yuan, Fengtai District, Beijing 100078. E-mail: lifangkai1324@163.com
LI Fangkai2*

résumé

ObjectiveTo explore the effects of Huoxue Jiedu Formula on the expression of the apoptosis-related factors B-cell lymphoma-2 (Bcl-2) and survivin in submaxillary gland cells in mice with Sjögren syndrome (SS).MethodsUsing 15 healthy C57BL/6J female mice as the blank control group. Seventy-five of non-obese diabetes mellitus female mice were classified as SS model. They were randomly assigned to the model group, total glucosides of paeony capsule group (TGP group, 0.233 g/kg), Huoxue Jiedu Formula low- (15.925 g/kg), middle- (31.850 g/kg), and high-dose (62.335 g/kg) groups, with 15 mice in each group. The blank control and model groups received distilled water by gavage, and the other groups received respective drug doses by gavage once a day for 8 consecutive weeks. After 1, 2, 4, 6, and 8 weeks of gavage, the salivary secretion volume of the mice was measured. The submaxillary gland index was calculated. Pathological changes in the submaxillary gland of mice were observed by hematoxylin-eosin staining. The expression of apoptosis-related factors Bcl-2 and survivin was detected by Western blotting and real-time fluorescence PCR.ResultsThere was statistical significance in salivary secretion volume from aspects of between-group, time-point, and interaction effects (P<0.05). After 8 weeks of treatment, compared to the blank control group, salivary secretion volume, submaxillary gland index, and protein and mRNA expressions of Bcl-2 and survivin in the model group were decreased, while the pathological score grading increased (P<0.05). Compared to the model group, the TGP group and the Huoxue Jiedu Formula low-, medium-, and high-dose groups showed an increase in saliva secretion after 8 weeks of treatment and an increase in submaxillary gland index, Bcl-2, and survivin mRNA expression levels, and a decrease in pathological score levels. The protein expressions of Bcl-2 and survivin in the Huoxue Jiedu Formula medium- and high-dose groups were increased (P<0.05). Compared to the TGP group, salivary secretion volume and submaxillary gland index in the Huoxue Jiedu Formula low-dose group were lower at weeks 4 and 6, while the pathological score grading was higher (P<0.05). The pathological score grading in the Huoxue Jiedu Formula high-dose group was lower. The protein and mRNA expressions of Bcl-2 in the Huoxue Jiedu Formula low- and medium-dose groups were lower (P<0.05).ConclusionHuoxue Jiedu Formula may relieve the submaxillary gland lesions and increase the salivary secretion volume of the submaxillary gland in SS model mice by regulating the expressions of apoptosis-related factors such as Bcl-2 and survivin in the submaxillary gland.

mots-clés

Huoxue Jiedu Formula;Sjogren syndrome;submaxillary gland;cell apoptosis;mice

References

  1. [1].
    LUPPI F, SEBASTIANI M, SILVA M, et al. Interstitial lung disease in Sjögren′s syndrome: a clinical review[J]. Clin Exp Rheumatol, 2020, 38 Suppl 126(4): 291-300.
  2. [2].
    FOX RI, FOX CM, GOTTENBERG JE, et al. Treatment of Sjögren′s syndrome: current therapy and future directions[J]. Rheumatology (Oxford), 2021, 60(5): 2066-2074.
  3. [3].
    HUANG L, LIU Q, ZHOU TT, et al. Deficiency of β-arrestin2 alleviates apoptosis through GRP78-ATF6-CHOP signaling pathway in primary Sjögren′s syndrome[J]. Int Immunopharmacol, 2021, 101(Pt A): 108281.
  4. [4].
    BENCHABANE S, SLIMANI-KADDOURI A, ACHELI D, et al. Association between increased bcl-2, fas and FasL levels and inflammation extent in labial salivary glands during primary Sjögren′s syndrome[J]. Endocr Metab Immune Disord Drug Targets, 2022, 22(3): 328-338.
  5. [5].
    李方凯,朱跃兰,侯秀娟,等. 活血解毒润燥方对干燥综合征小鼠颌下腺细胞凋亡抑制因子Survivin表达的影响[J]. 中国实验方剂学杂志,2021, 27(24): 84-91.
  6. [6].
    周新尧,姜泉,唐晓颇,等. 干燥综合征中医证候专家共识[J]. 北京中医药大学学报,2023, 46(3): 310-314.
  7. [7].
    梁亦欣,黄小娟,刘小平,等. 基于“燥、毒、瘀”理论探讨中医治疗干燥综合征合并间质性肺疾病[J]. 西部中医药,2023, 36(12): 37-41.
  8. [8].
    国生,崔霞,薛小娜,等. 振腹疗法联合活血解毒方干预原发性干燥综合征的疗效观察[J]. 世界中医药,2020, 15(23): 3675-3679.
  9. [9].
    毛晓娟. 干燥综合征患者外周血中Treg和Th17细胞绝对数量与肠道微生物菌落特征的相关性研究[D]. 太原:山西医科大学,2020.
  10. [10].
    文凤,李清,李萃,等. 东莨菪碱法和高渗盐水法复制小鼠干燥综合征模型的比较[J]. 中国免疫学杂志,2023, 39(2): 261-266.
  11. [11].
    MANFRÈ V, CAFARO G, RICCUCCI I, et al. One year in review 2020: comorbidities, diagnosis and treatment of primary Sjögren′s syndrome[J]. Clin Exp Rheumatol, 2020, 38 Suppl 126(4): 10-22.
  12. [12].
    LI YF, BOOKMAN AAM. Comparison of effect on sicca symptoms of anticentromere antibody-positive Sjögren syndrome and primary Sjögren syndrome alone[J]. J Rheumatol, 2020, 47(6): 876-880.
  13. [13].
    NEGRINI S, EMMI G, GRECO M, et al. Sjögren′s syndrome: a systemic autoimmune disease[J]. Clin Exp Med, 2022, 22(1): 9-25.
  14. [14].
    ZHU H, ZHENG J, ZHOU Y, et al. Knockdown of RSAD2 attenuates B cell hyperactivity in patients with primary Sjögren′s syndrome (pSS) via suppressing NF-κb signaling pathway[J]. Mol Cell Biochem, 2021, 476(5): 2029-2037.
  15. [15].
    HUANG L, CHEN GS, CHEN Y, et al. Inhibition of melanoma by survivin-specific lymphocytes combined with CCL17 and granulocyte-macrophage colony-stimulating factor in a mouse syngeneic model[J]. Anticancer Drugs, 2021, 32(2): 138-147.
  16. [16].
    MAMRIEV D, ABBAS R, KLINGLER FM, et al. A small-molecule ARTS mimetic promotes apoptosis through degradation of both XIAP and Bcl-2[J]. Cell Death Dis, 2020, 11(6): 483.
  17. [17].
    LI N, LI YS, HU JW, et al. A link between mitochondrial dysfunction and the immune microenvironment of salivary glands in primary Sjögren′s syndrome[J]. Front Immunol, 2022, 13: 845209.
  18. [18].
    何加乐,周新尧,李达,等. 基于叶桂“上燥治气,下燥治血”理论探讨干燥综合征的发病与辨治[J]. 中医杂志,2023, 64(23): 2401-2406.
  19. [19].
    邓予新,孙鼎,顾军花,等. 养阴清热活血法治疗干燥综合征的临床舌象研究[J]. 西部中医药,2022, 35(10): 107-111.
  20. [20].
    姜利芳,刘璐,李雪梅. 益气养阴、活血祛风治疗原发性干燥综合征[J]. 吉林中医药,2021, 41(6): 763-766.
  21. [21].
    王皓,刘英,姜萍. 基于“燥毒-玄府”理论辨治干燥综合征撷粹[J]. 江苏中医药,2023, 55(1): 52-54.
  22. [22].
    石岩硕,邱学佳,赵建群,等. 白芍总苷胶囊联合羟氯喹治疗干燥综合征临床疗效的系统评价[J]. 中国医院用药评价与分析,2022, 22(12): 1502-1506.
  23. [23].
    陈爱党,康宁,郭建洲. 白芍总苷胶囊联合来氟米特治疗对类风湿关节炎患者炎性因子、心肌酶谱及不良反应的影响[J]. 实用医院临床杂志,2022, 19(5): 131-134.
  24. [24].
    王海瑜,张玉婷,柏志义,等. 活血解毒方对NOD小鼠肠道菌群的影响[J]. 中医杂志,2022, 63(1): 56-63.
  25. [25].
    闻志轲,王丽莹,高青杰,等. 孟庆良基于“阴虚燥毒”理论治疗干燥综合征[J]. 中医学报,2023, 38(4): 776-780.
  26. [26].
    王庆,李天一,吴国琳,等. 养阴益气活血方对干燥综合征NOD小鼠颌下腺BCL-6和CXCR5表达的影响[J]. 中国免疫学杂志,2020, 36(3): 261-266.
  27. [27].
    霍晓萌. 活血解毒方联合硫酸羟氯喹治疗干燥综合征疗效及对Th17/Treg免疫失衡的影响[J]. 现代中西医结合杂志,2018, 27(12): 1331-1333.
  28. [28].
    张赛,沈正东,郑凌琦,等. 活血解毒方对HSG细胞凋亡中Caspase家族及关键蛋白的影响[J]. 中华中医药杂志,2023, 38(7): 3310-3313.
  29. [29].
    傅天啸,李天一,吴方平,等.基于NF-κB P65/IκBα信号通路探讨养阴益气活血方治疗干燥综合征作用机制[J].中国中西医结合杂志,2022,42(9):1095-1100.

Lire l'article complet

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website